Plain-English translation of NCT05733416 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Some strokes happen without a clear cause — doctors call these cryptogenic strokes. This trial is testing whether adding a special imaging scan called FDG PET/CT to standard cancer screening can find hidden cancers that might be linked to these unexplained strokes. The goal is to see if this more intensive screening approach catches more cancers than regular screening alone.
When someone has an unexplained stroke, doctors wonder if a hidden cancer might be involved. This trial exists to find out whether screening more carefully with advanced imaging can catch these cancers earlier, which could help improve treatment and outcomes for stroke patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will receive the standard cancer screening recommended for your age and risk factors. The other group will receive that same standard screening plus an additional advanced imaging scan called FDG PET/CT. The study takes place at Ottawa Hospital and involves a single visit where you'll have the imaging scan if you're assigned to that group.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Canada
Collaborators
Brain Canada, Heart and Stroke Foundation of Canada
Enrollment target
~45 participants
Started
September 2023
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dariush Dowlatshahi, MD PhD
Ottawa Hospital Research Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.